89bio reports first quarter 2024 financial results and provides corporate update

–initiated phase 3 enlighten-fibrosis trial in non-cirrhotic (f2-f3) metabolic dysfunction-associated steatohepatitis (mash) patients–

ETNB Ratings Summary

ETNB Quant Ranking